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ENDOCRINOLOGY
THE EFFECTIVENESS OF MULTINODULAR LARGE TOXIC GOITER
THERAPY USING 131-I
 M. Bączyk, M. Pisarek, K. Ziemnicka, H. Stankowiak-Kulpa, P. Gut, M.
Gryczyńska, J. Sowiński
Department of Nuclear Medicine & Endocrinology K. Marcinkowski University
School of Medical Sciences Poznań, Poland
The treatment of multinodular large toxic goiter is still the actual clinical problem, especially
when therapy with antithyroid drugs is ineffective, there are some side effects after such
a therapy or the surgery is not possible (the contraindications, disagreement of patient ). The
aim of study was to establish the effectiveness of radioiodine therapy using 131-I in the group
of patients with multinodular large toxic goiter. The examined group included 17 women (aged
62–82). In all patients multinodular large toxic goiter (size by USG more then 100 ml) was
detected. The mean of goiter volume in examined group was 195 ml (range 100–370). The
hormonal profile (TSH, FT4, FT3), anti-thyroid antibodies ( aTPO, aTG, TSHAbTRAK) serum
level, growth factors (insulin, IGF-1, GH) serum level were estimated. The radioiodine uptake
after 5 and 24 hours, 131-I thyroid scintigraphy and USG guided fine needle aspiration biopsy
were done. No malignant nodules were detected. Each patient started from 30 mCi doses of
131-I fractionated therapy. The control study and next 131-I dose (30 mCi 131-I) was repeated
every 3 months. After 6 months (and after total dose of 60 mCi of 131-I) we found: 10 patients
(59%) with clinical and laboratory euthyroidism, 6 patients (35%) with hyperthyroidism and
1 patient (6%) with hypothyroidism (L-thyroxine substitution was started and 131-I therapy was
continued because of large goiter). The mean of goiter volume decreased to 147 ml (range
67–297). After 9 months (and after total 90 mCi 131-I dose) we found: 12 patients (71%) with
clinical and laboratory euthyroidism, 2 patients (12%) with hyperthyroidism and 3 patients
(17%) with hypothyroidism. The mean of goiter volume decreased to 123 ml (range 56–217).
In 16 cases radioiodine therapy for thyroid ablation is continued. No correlations between
decrease in thyroid volume, radioiodine uptake and anti-thyroid antibodies levels were detect-
ed (p > 0.05). In the period of 9 months, no statistically significant changes of radioiodine
uptake, anti-thyroid antibodies, growth factors levels were observed (p > 0.05).
Conclusions:
1. In some cases of of multinodular large toxic goiter, the radioiodine therapy can be the best
alternative way for antithyroid drug and surgery therapy.
2. The fractionated radioiodine therapy of multinodular large toxic goiter is safe and effective
method but continuation of nodules observation is necessary.
3. The effectiveness of fractionated radioiodine therapy gradually decreases and partially de-
pends on TSH level (the necessity of long-term monitoring and, if it is necessary - thyroxine
substitution therapy ).
DIFFERENTIATED THYROID CARCINOMA — EXPERIENCES WITH
RADIOIODINE TREATMENT IN CHILDREN
R. Czepczyński1, K. Ziemnicka1, M. Bączyk1, M. Niedziela2, J. Sowiński1
1Dept. of  Endocrinology and Metabolism, 2Dept. of Endocrinology
and Diabetology of Development Age, University School of Medical
Sciences, Poznan, Poland
Introduction: Differentiated thyroid carcinoma (DTC) is a rare tumor in children and
adolescents. Similarly to the adults, radioiodine therapy plays an important role
in the management of DTC in the development age. Aim of the study was to evaluate the
efficacy of radioiodine therapy in children treated in our center from 1999 to 2003.
Material and methods: Up to now, 37 children with DTC were treated with radioiodine
in our department, i. e. 4.6% of all patients with DTC. 32 girls and 5 boys were 9 to 18
years old (mean 15.3 ± 2.2 years) at the time of the first ablation treatment. Histological-
ly, papillary carcinoma was diagnosed in 27 children (73.0%) (follicular variant in 8 chil-
dren [21.6%]), follicular carcinoma — in 9 children (24.3%) and oxyphilic carcinoma —
in 1 case (2.7%). In 8 children multifocal form of carcinoma was diagnosed. In 5 children
(13.5%) cervical lymph node metastases were found. In two of these children additional-
ly distant DTC metastases were diagnosed. The radioiodine whole body scan was per-
formed during endogenous stimulation of TSH. TSH concentrations were from 32 to 310
mU/l (mean 127 ± 54; median 108). Concentration of thyroglobulin was from 0,26 to
302 ng/ml (mean 22 ± 65; mediana 3.6). Volume of the thyroid tissue remnants after
thyroidectomy assessed by ultrasound was from 0.05 to 2.27 ml. All children were treat-
ed with ablation doses of radioiodine of activity from 50 to 90 mCi (mean 64 ± 11).
Results: Until now, 30 children (81.1%) were subjected to radioiodine diagnostics
again, ca. 6 months after ablation treatment. In 20 of them (66.7%) complete remis-
sion was diagnosed and in these children no further radioiodine treatment was re-
quired. Indications for the second radioiodine treatment were present in the remaining
10 children (33.3%) who received radioiodine with activity from 60 to 150 mCi depend-
ing on individual staging. Eight out of these children have been already referred to us
for the third radioiodine whole body scan. In all of them complete remission was ob-
served. They are now followed up in the outpatient clinic according to the manage-
ment guidelines.
Conclusion: Radioiodine treatment is an effective method in children with DTC
— in 2/3 of patients effective ablation was achieved after the first radioiodine therapy,
in the remaining 1/3 — after the second course of radioiodine treatment.
QUALITY OF LIFE IN GRAVES’OPHTALMOPATHY
I. Warmuz-Stangierska, A. Czarnywojtek, R. Stangierski, J. Sowiński
Department of Endocrinology, Poznań University School of Medical Sciences,
Poznań, Poland
The methods of Graves’ disease treatment have been modified during latest twenty
years. The main symptom which determined specific emotional reaction was al-
ways orbitopathy. The negative effect of orbitopathy seems to be the most impor-
tant problem influencing the health-related quality of life (HRQL) in Graves’ patients.
The notion “quality of life” which appeared in scientific publication in 80-ths is de-
scribed as great influence of disease and treatment on patients life.
The aim of our study was exploration of some psychological functions and their role
in ophtalmmopathic patients’ quality of life .
We examined 48 women with Graves’ ophtalmopathy (GO) aged from 32 to 64 yr.,
average 43 SD = 8.17. All women were actively working until the hospitalisation.
They were asked to complete the experimental questionnaire based on London’s
St. George Hospital (in our modification). We used also: Temperament Inventory
(EAS-D) in addition for adults, estimating: emotionality-distress, emotionality-fear,
emotionality-anger, activity, and sociability, STAI Questionnaire (State-Trait Anxiety
Inventory) and Beck’s Depression Scale. We compared the scores with two refe-
rence populations of ‘healthy’ persons and to “GO “patients. All patients were invit-
ed for a follow-up ophthalmologic examination.
We have interpreted obtained results as: 1. anxiety tendency,  2. subjective de-
creased mood, 3. decreased social tendency.
Obtained results let us to conclude that in examined group:
1. There is tendency to fear and anxiety reactions and to avoid danger situations
and person.
2. There is subdepressive mood.
3. There is low social tendency (social isolation).
4. Decreased quality of life is connected with eyes symptoms/pains, discomfort,
vision problems and decreased subjective attraction.
5. Eyes’ problems generate: social avoiding, job troubles absence, less efficiency,
resignation/and economical status’ decrease.
EARLY EFFICACY OF ABLATION WITH FRACTIONATED RADIOIODINE
IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA
R. Czepczyński, K. Ziemnicka, M. Bączyk, M. Ruchała, R. Oleksa, J. Sowiński
Dept. of Endocrinology and Metabolism, University School of Medical Sciences,
Poznan, Poland
Introduction: Treatment of differentiated thyroid carcinoma (DTC) includes ablation with ra-
dioiodine under endogenous TSH stimulation. According to the guidelines, patients without
lymph nodes or distant metastases are treated with 60 mCi (2.2 GBq) of 131-I. Current
regulations accept treatment with such high activities only in the conditions of specialized
wards equipped with a sewage decontamination system. From 1999–2002, due to deficien-
cy of such hospital beds in the region, part of DTC patients were treated on an outpatient
basis with fractionated 131-I doses. Aim of this study was to evaluate, whether the use
of fractionated radioiodine did not affect the efficacy of ablation.
Material and methods. Out of 642 patients with DTC who were treated with radioiodine from
1999 to 2002 in our center, 366 patients treated with 131-I for the first time 1–3 months after
total thyroidectomy were retrospectively selected. According to the mode of treatment, the
patients were retrospectively assigned into one of two groups: Group 1–treatment with
a single activity of 60 mCi (77 patients, 21.1%); Group 2 — treatment with two activities of
30 mCi administered every 24 hours (289 patients, 78.9%). As advised by the guidelines, all
patients were subjected to a radioiodine diagnostics 6–9 moths after ablation, during dis-
continuation of L-thyroxin suppression, comprising measurement of: TSH and thyroglobulin
(Tg) concentrations, 24 hours iodine uptake (U 24), volume of the remnant thyroid tissue by
ultrasound (V) and a whole body scan. Patients with partial remission, stagnation or progres-
sion of the disease were qualified to the second radioiodine treatment (singlese activity) and
patients with complete remission were sent to further outpatient follow-up. Early success rate
(SR) of the ablation was the percentage of patients with complete remission. SR in both
groups was compared.
Results: Both groups were comparable in terms of sex and age structure. During the primary
diagnostic before ablation no statistical difference of TSH, Tg, U24 and V was found.
The same parameters obtained during the secondary diagnostics 6–9 months after ablation
were as follows (mean ± SD; median):
Tg (ng/dl) U24 (%) V (ml)
 Group 1 10.8 ± 55.2; 0.9 1.17 ± 1.18; 0.9 0.17 ± 0.33; 0.05
 Group 2 7.1 ± 68.6; 0.62 1.14 ± 1.17; 0.9 0.19 ± 0.61; 0.06
 p 0,012 ns ns
Complete remission was achieved in 43 patients from group 1 and in 177 patients from
group 2 (SR 55.8% v. 61.2%, p = ns). As soon as the adequate hospital ward with a decon-
tamination system was organized and the regulations of ambulatory treatment were modi-
fied, therapy with fractionated doses of radioiodine was abandoned.
Conclusion: Treatment  with fractionated doses of radioiodine did not significantly influence
the early efficacy of ablation in patients with DTC.
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CHANGES OF LV VOLUMES AFTER PHYSICAL STRESS
IN PATIENTS WITH CAD
W. Cholewinski, B. Stefaniak, A. Tarkowska
Chair and Department of Nuclear Medicine, Medical University of Lublin, Poland
Background: Our previous observations showed a post-stress reduction of LVEF
in patients with CAD, increasing between 1st and 3rd hr after termination of exercise.
The aim of this study was to check the effect of the physical exercise on the LV
volumes.
Material and methods: Fifty five pts with CAD and 9 healthy subjects (NMS) were
studied. All subjects underwent gSPECT 1 hr after tetrofosmin administration at rest
(R) and, on the next day, 1 hr (S1) and 3 hrs (S3) after tetrofosmin injection at peak
physical stress. Data were acquired using a double head camera, over a 180° circu-
lar orbit. LV end-diastolic (ED) and end-systolic (ES) volumes were calculated using
a commercially available QGS software.
Results: In CAD ES volume was equal to 51.8 ± 37.8 at R, 52.4 ± 35.6 at S1 and
55.7 ± 38.6 at S3. No significant differences were found between R and S1 values.
On the other hand, comparisons between R and S3 as well as between S1 and S3
ES values revealed highly significant differences, with p < 0.001. The increase in ES
volumes between R and S1 were observed in 21/55 pts (38 %) and between R and
S3 in 37/55 pts (67 %). In NMS, ES volume amounted to 29.9 ± 10.3 at R, 35.9 ±
± 18.5 at S1 and 35.9 ± 16.7 at S3, with no statistically significant differences
between those values. The average ES values were at each time-point higher in
CAD than in Nms, although the differences were not significant. In each group LV
ED volumes measured by all three examinations were similar to each other (CAD:
101.5 ± 46.4, 99.1 ± 43.2, 99.7 ± 46.1, respectively) (NMS: 74.8 ± 20.0, 75.0 ±
± 19.0, 74.3 ± 21.2, respectively). Similarly to ES, ED values were at each time-
point distinctly higher in CAD than in NMS, although the differences were not signif-
icant. In CAD, both ED and ES volumes calculated from data acquired during all
three examinations showed significant negative correlations with LVEF (p < 0.001).
Conclusions: In the majority of pts with CAD, physical stress leads to an increase in
the left ventricular ES volume.
The post-stress increase in the ES volume grows stronger between 1st and 3d hr
after termination of exercise.
Reduction in LVEF occurring in pts with CAD after exercise depends mainly on the
enlargement of the ES volume.
EVIDENCE FOR EXTRAVASATION OF INTRACORONARY ADMINISTERED
BONE-MARROW DERIVED CD34+ STEM CELLS IN PATIENTS WITH
ACUTE MYOCARDIAL INFARCTION
T. Siminiak, R. Czepczyński, D. Fiszer, M. Majewski, B. Grygielska,
O. Jerzykowska, M. Kurpisz, J. Sowiński
Dept. of Endocrinology and Metabolism, University School of Medical Sciences,
Poznan, Poland
Background: Increasing experimental data as well as initial in-man experience indi-
cate that bone marrow — derived stem cells do have a potential for myocardial
regeneration. The protocols of currently ongoing clinical phase 2/3 trials evaluating
functional benefits of bone marrow-derived stem cells do involve intracoronary ad-
ministration of autologous bone marrow stem cells (BMC), although a direct evi-
dence of BMC cells extravasation and tissue migration after intracoronary adminis-
tration is missing.
Aim: The purpose of the study was to evaluate the extravasation and tissue migra-
tion of autologous CD34+ stem cells after intracoronary administration in patients
with acute myocardial infarction (AMI).
Material and methods: 8 patients that underwent AMI treated with primary PTCA
of a proximal lesion in one of the main coronary arteries were included into the
study. In all patients, at day 2–6 after AMI onset, under local anesthesia, ca 30 ml of
bone marrow aspirate was obtained by sternal puncture and CD34+ cells were
isolated from bone marrow aspirate by magnetic cell sorting using the Dynal® CD34
Progenitor Cell Selection System. This kit contains Dynabeads® for the positive iso-
lation of the CD34+ cells plus DETACHaBEAD® for the release of the captured cells
(from the beads). Cells were subsequently labeled with 0.4–0.8mCi (15–30MBq)
of 111-Indium-oxinate (Mallinkrodt). Cell suspension was administered sub-selec-
tively intracoronary into the infarct-related artery at the time of a brief coronary flow
decrease. An over-the-wire balloon was inflated for 120 seconds and cells were
delivered via the internal catheter lumen. Whole-body scans using a double-head
Varicam gamma camera were performed in each patient after 24 hours.
Results: Main regions of uptake were detected over liver, spleen and heart. Based
on evaluation of activity in the regions of interest, we estimated that 1–11% of injec-
ted activity was concentrated in the heart, whereas uptake in the spleen and the
liver was 3–17% and 12–45% of total injected activity, respectively.
Conclusions: Our preliminary data provide evidence for stem cell extravasation
and tissue migration after intracoronary administration in patients with AMI. De-
tailed studies evaluating possible correlations of stem cell tissue migration with cell
administration protocol used as well with clinical data, including the time of primary
PTCA after AMI onset and timing of cell administration, are needed.
APPLICATION OF DIPIRYDAMOLE STRESS TC-99MIBI SPECT
IN PATIENTS WITH SIGNIFICANT AORTIC STENOSIS
M. Kostkiewicz, W. Szot, A. Mura, A. Leśniak-Sobelga, M. Olszowska, W. Tracz
Background: Exercise cardiac stress testing in patients with significant aortic stenosis
is generally avoided for safety reasons. Furthermore, the studies that actually ad-
dressed  the value of exercise testing both with and without myocardial Tc99MIBI
scintigraphy for the diagnosis of coronary artery disease (CAD) proved to yield low
specificity. Nowadays  there are no safe and accurate means for noninvasive as-
sessment of the presence, extent and severity of CAD in patients with significant
aortic stenosis. Our study aimed to assess overall safety and usefulness of dipiry-
damole stress myocardial perfusion scintigraphy for detection of CAD using single-
photon emission computed tomography (SPECT) in patients with aortic stenosis.
Material and methods: The study comprised 20 patients with significant aortic
stenosis who were compared with 20 patients with CAD designated as CCS II and
III. All patients underwent a 5-minute dipirydamole infusion (1.5 mg/kg body weight)
protocol stress technetium-99m sestamibi SPECT. Visual 17-segment SPECT anal-
ysis used a standard five-point scoring system ranging from 0 (normal tracer up-
take) to 4 (absent uptake). The SPECT results were considered abnormal if more
than two segments had a stress score 3 2. These results were compared to the
same number of patients diagnosed with CAD. All patients also underwent coro-
nary angiography procedure. The respective results in the groups were subsequently
compared using the U-Mann-Whitney test and Pearson’s correlation nonparamet-
ric test.
Results: Sensitivity of gated SPECT study was calculated at the level of 83% in the
studied group vs. 100% in the controls, with positive predictive value at 88% vs.
90%, respectively.
Hemodynamic responses during dipirydamole stress testing demonstrated no sig-
nificant differences in the net change in systolic blood pressure (30% vs. 25%, pa-
tients with aortic stenosis vs. control subjects), heart rate (20% vs. 20%), dyspnea
(25% vs. 30%) or incidence of chest pain (30% vs. 30%).
Conclusions: Dipirydamole Tc99m MIBI SPECT study was established to be well
tolerated, safe and diagnostically accurate in patients with significant aortic stenos-
is and suspected CAD.
INFLUENCE OF PREVIOUS HYPERTHYREOIDISM ON ABLATIVE
RADIOIODINE TREATMENT OF DIFFERENTIATED THYROID CARCINOMA
R. Czepczyński, P. Bolko, K. Ziemnicka, M. Bączyk, M. Ruchała, J. Sowiński
Dept. of Endocrinology and Metabolism, University School of Medical Sciences,
Poznan, Poland
Introduction: In some patients with hyperthyroidism, differentiated thyroid carcinoma (DTC)
is diagnosed after surgery. As all patients with DTC, they are then subjected to thyroid ablation
with radioiodine. Theoretically, previous hyperthyroidism influencing iodine metabolism may
decrease the effective dose of radioiodine and thus limit the efficacy of ablation. Aim of this
study was a retrospective analysis of efficacy of radioiodine treatment in patients with DTC who
had been treated for hyperthyroidism.
Material and methods: Out of 579 patients with DTC who were treated in our department
between 1999 and 2003 and who had been subjected to at least one control radioiodine
diagnostics 6–8 months after ablation, patients who had been diagnosed and treated for
hyperthyroidism before surgery were retrospectively selected, constituting Group H.
The remaining patients in whom hyperthyroidism had never been diagnosed were included
in the control group (Group C). Ablation success rate (SR) as assessed in the first control
diagnostics 6–8 month after ablation in both groups was compared.
Results: 69 patients (11.9%) aged 11–76 years (median 52 yrs) were qualified to Group H.
The Group C consisted of 510 patients (88.1%) aged 12–84 yrs (median 50 yrs). Papillary
thyroid carcinoma was relatively more frequent in Group H than in Group C (H — 89.8%,
C — 80.4%); follicular thyroid carcinoma — slightly more frequent in Group C (H — 10.1%,
C — 15.5%). Lymph nodes metastases were found in 5 patients of Group H (7.2%) and
72 patients of Group C (14.1%). Parameters obtained during the first radioiodine diagnos-
tics in both groups are listed in the table 1:
Table 1.
Group H Group C p
TSH [mU/l] 61.6 ± 51.4 77.0 ± 46.1 < 0.05
Tg [ng/ml] 44.8 ± 147.8 35.4 ± 111.0 ns
Iodine uptake at 24 h (%) 6.8 ± 6.9 5.8 ± 5.7 NS
Volume of thyroid remnants in US [ml] 1.1 ± 0.8 1.6 ± 5.5 NS
All the patients were treated with ablative dose of radioiodine and 6–8 months later a con-
trol diagnostics was performed. Based on ultrasound of the neck, Tg concentration, iodine
uptake and whole body scan, complete remission was diagnosed in 34 patients of Group H
(SR = 49.2%) and in 294 patients of Group C (SR = 57.6%). The difference in SR was not
significant (test c2).
Conclusion: Previous hyperthyroidism did not significantly influence the early effect
of radioiodine ablation in patients with DTC.
CARDIOLOGY
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UTILITY ASSESSMENT OF IN VIVO LABELED RED BLOOD CELLS
IN IMAGING HEMODYNAMIC DISORDERS OF VENOUS SYSTEM
OF LOWER LIMBS POST SUBCUTANEOUS INJECTION 99m-TECHNETIUM
A. Stępien1, J. Pawlus1, M. Dziekiewicz2, J. Sroga3, T. Puto4
1Department of Nuclear Medicine, 5th Clinical Military Hospital, Cracow, Poland,
2Department of General, Oncological and Vascular Surgery, Military Institute of
Medicine of Ministry of Defense, Warsaw, Poland, 3 Clinic of General Surgery, 5th
Clinical Military Hospital, Cracow, Poland, 4Department of Radiology, 5th Clinical
Military Hospital, Cracow, Poland
Introduction: The venous insufficiency (VI) of lower limbs is the most widespread
disease and its frequency still increase. The earlier stage of VI can be non-symp-
tomatic. The Doppler ultrasound technique is the most common diagnosis method
using in recognizing disorders of venous circulation of the lower limbs. Other useful
method can be radioisotope technique as phlebography, which allows to functional
evaluation of disorders of venous circulation of the lower limbs. This method has
a very important  sense in questionable results of standard diagnosis examination.
Aim of the study: The purpose of this study was utility evaluation of radioisotope
phlebography using in vivo labeled red blood cells in the venous insufficiency of the
lower limbs diagnosis.
Material and method: Analysis included 26 patients (17 women, 9 men, mean age
51 years). Each patient received intravenous 5 ml methylenediphosphoniane (Am-
ersham). Than after 15 minutes (apply pressure above ankles) each patient was
injected subcutaneous (in web space of the both feet) 99m-technetium with activity
150–200 MBq. Static acquisition with the use of X-Ring gamma camera (from feet
to pelvis, move 10 cm/min) has been started after 3 minutes post injection of the
isotope and  next  acquisition with decompression was performed.
Results: In all patients good quality functional images of the venous vessels of the
lower limbs were visualized. There was now case of any local or general  undesir-
able symptoms post injection of the radiotracer. In 8 patients normal  functional
image of venous vessels were observed, whereas in 18 cases disorders in venous
circulation (block in deep veins outflow and insufficiency of perforating veins) were
shown. Results of radioisotope phlebography confirmed in 25 cases with results of
ultrasound examination. Only in one case radioisotope phlebography was shown
disorders of venous circulation of the legs despite  normal ultrasound investigation.
Conclusions: Relatively long-time subsists of the tracer in the intravenous space
and good layout of the radioactivity in venous vessels include significant advantag-
es of this method. Radioisotope phlebography using in vivo labeled red blood cells
can be technique with choice in cases of difficulty in intravenous injection of the
radiofarmaceuticals due to oedema.
DIAGNOSTIC EFFICACY OF 131I ALPHA METHYLTHYROSINE SCINTIGRAPHY
(SPECT/MR FUSED IMAGES) FOR DETECTION IF THE RECURRENCE
OF BRAIN GLIOMAS
M. Górska-Chrząstek1, P. Grzelak2, M. Bienkiewicz1, P. Gasiński3, K. Tybor3,
E. Zakrzewska4, R. Mikołajczak4, B. Góraj2, J. Kuśmierek1
1Department of Nuclear Medicine, Medical University of Łódź (MUL), 2Department
of Radiology — Medical Imaging, MUL, 3Clinical Department of Neurosurgery,
MUL, 4POLATOM Isotope Centre, Swierk, Poland
Basic assumptions and objective: Radical treatment of gliomas includes surgery and radiothera-
py. In majority of cases, however, there occurs a recurrence, and the most important factor influenc-
ing clinical success of further treatment is its early detection as well as differentiation of the neoplas-
tic growth from a present scar and radiation effects.
The first tool used at present for above purpose is MRI investigation. In some proportion of cases
results of MRI are inconclusive and possibility of relapse remains still as suspicion. Scintigraphy with
labelled aminoacids, both by applying PET and SPET techniques remain as possible alternative
because neoplastic cells demonstrate avid uptake of protein precursors.
In our studies 131I alphamethylthyrosine, a radiopharmaceutical manufactured in Poland, has been
used. This 131I labelled compound is much less expensive that the 123I labelled analogue; use of 131I,
although delivering higher dose, was found justified in patients with already diagnosed malignancy.
Head images obtained by means of MRI and SPET scintigraphy, have been fused by means of
a specially designed computer programme.
Objective of the study was assessment of clinical efficacy of the above mentioned procedure when
applied to early detection of glioma relapse.
Material and methods: 21 patients have been studied who had been surgically treated and subse-
quently irradiated because of the diagnosed glioma of the brain (III/IV grade of malignancy acc to
WHO classification). MRI has been performed using a 1.55 Magnetom Vision Plus (Siemens) unit in
T1 dependent mode, before and after Gd DTPA i.v. administration. SPET scintigraphy of the brain
was performed using a double head gamma cammera (ELSCINT), using a high  energy collimator.
A 64x64 matrix was applied with 35 sec. step by step acquisitions starting 15 min after intravenous
administration of the radiopharmaceutical (RF) at activity of 74 MBq.
In patients with increased focal uptake of the RF a site of the highest uptake was delineated in the
matrix and a count-rate quotient tumour/non-tumour calculated.
Images were fused applying a 3D overlying technique using a PC working station. The procedure
was based on statistical analysis of 3 dimensional distribution of voxels with maximization of statis-
tical probability (mutual information).
Results: In 13 patients the MRI imaging disclosed presence of a polymorphic focus suggesting a
tumour recurrence. In 8 subjects the result was equivocal due to presence of post surgery and
irradiation sequelae. In all 13 patients with a positive relapse in the MRI diagnosis and in 4 with the
equivocal image there was an enhanced RF uptake in SPET image. In 4 patients the scintigraphy
yielded a negative result. SPET/MRI image fusion enabled a topographic localisation of the area
with the peak activity, in most cases corresponding to the solid tumour visualised in MRI. In
4 patients the fused image indicated precise localisation of the relapse in the suspected region.
Verification of the results was made by means of tumour MRI spectroscopy and/or by histology
investigation of the tissue fragments, obtained by means of stereotactic biopsy or during surgery.
Conclusions: The SPET study utilising 131I alphamethylthyrosine enables confirmation of the pres-
ence of neoplastic tissue in a morphologically identified area that may correspond to the site of
tumour glioma recurrence. In equivocal MRI images the scintigraphy may disclose or exclude re-
lapse. The fused MRI/SPET images form a very useful tool for selection of the site for mR spectros-
copy and for tissue sampling by means of stereotactic biopsy. The results can also be used for
planning the brachytherapy. It seems also important that 131I alphametylthyrosine yields images of
good quality.
DaTSCAN AND SPET IN THE DIAGNOSTICS PARKINSON’S DISEASE
AND PARKINSONIAN SYNDROMES
K. Chmielowski1, B. Brodacki2, N. Szaluś1, E. Skrobowska3, J. Pietrzykowski,1
J. Kotowicz2
1Department of Nuclear Medicine, 2Department of Neurology, Department
of Medical Radiology Military Institute of Health Services, Warsaw, Poland
The aim of this study was to verify the diagnostic value of the radiopharmaceutic
[123I]FP-CIT (DaTSCAN) in functional imaging of the presynaptical dopaminergic
system in patients with Parkinson’s disease and parkinsonian syndromes: multiple
system atrophy, orthostatic hypotonia Shy-Drager, essential tremor. Material and
methods: that pilot study group investigated of 8 patients in which either preliminary
diagnosis or suspicion of Parkinson’s disease, parkinsonian syndrome or multiple
system atrophy was set. Imaging of the brain with SPET (dual head detector Vari-
cam Elscint) and MRI were performed. The radiopharmaceutic DaTSCAN was ad-
ministered intravenously in the dose 145-148 MBq. SPET images were reconstruct-
ed by filtered backprojection with the use of Butterworth filter. The images were
inspected visually. Images from SPET and MRI were superimposed by means of
the workstation Hermes (Nuclear Diagnostics) with designated regions of interest
(ROI) in the striatum and occipital cortex in order to assess semiquantitatively the
binding of dopamine transporter. Results; from the group of 8 patients evaluated
with the use of DaTSCAN four had normal results, and four — abnormal. The pre-
liminary diagnosis was sustained in 3/8 of patients (including Parkinson’s disease
in two patients and multiple system atrophy in one patient). In the remaining 5 pa-
tients the preliminary diagnosis was changed, namely: in 2 cases the essential tremor
was diagnosed, in 1 case — Parkinson’s disease, in 1 case — orthostaic hypotonia
Shy-Drager , and in 1 case — despite the tremor of the upper limbs results were
normal. In all 8 patients the tracer proved to be useful in the confirmation of clinical
diagnosis, especially in the differentiation between the essential tremor and Parkin-
son’s disease. In the case of multiple system atrophy the imaging revelaed signifi-
cant loss of nigrostriatal dopaminergic neurons. Such loss was observed also in the
cases of Parkinson’s disease affecting the posterior parts of the striatum.
Conclusions: [123I]FP-CIT (DaTSCAN) is the radiofarmaceutic which enables in-
sight into the function of dopaminergic neurons in the nigrostriatal system and is of
diagnostic value in differentiation between Parkinson’s disease and essential trem-
or, and parkinsonian syndromes.
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INDUCTION OF RADIOIODINE UPTAKE IN NON-FUNCTIONING
METASTASES OF DIFFERENTIATED THYROID CANCERS — IS THERE
A ROLE FOR REDIFFERENTIATION THERAPY WITH 13 CIS RETINOIC ACID
D. Handkiewicz-Junak, J. Roskosz, Z. Puch, K. Hasse-Lazar, A. Kukulska,
Z. Wygoda, S. Szpak, B. Jarząb
Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-
Curie Memorial Institute, Gliwice Branch, Poland
Cellular dedifferentiation and resulting loss of radioiodine avidity occurs in about
1/3–1/2 of patient with the diagnosis of differentiated thyroid cancer (DTZ). In that
case no efficient therapeutic methods have been developed up to now. Laboratory
studies on redifferentiation effect of 13 cis retinoic on thyroid cancer cells may be-
come a solution to this problem.
The aim of the study was to evaluate role of 13 cis retinoic acid in an induction of
radioiodine avidity in non-functioning metastases of DTC.
Material: Thirty four patients suffering from distant metastases or locoregional re-
currence of DTC that did not show radioidine uptake in post-therapy scintigraphy
were included into the study. 13 cis retinoic acid (Roaccutan®) was administered for
6 weeks before radioiodine therapy (for the first 7 days 1 mg/kg of body weight,
than 1.5 mg/kg). Radioiodine therapy was performed with the aid of human recom-
binant TSH (Thyrogen®) — 0.9 mg i.m. during two consecutive days. On the third
day 100 mCi of radioiodine was administered. Post-therapy whole body scintigra-
phy was performed on the day six.
Results: On post-therapy scintigraphy radioiodine uptake was visible in 7/34 (21%)
of the treated patients. Age of the patient, histological type of the cancer and time
from thyroid cancer diagnosis did not correlated with the probability of radioiodine
uptake induction. Serum thyroglobulin level before and after retinoic acid application
did not show any statistical significant differences (1123 v 1254 ng/ml; p > 0.05).
Eleven patients (32%) were lost from observation, and the median time of observa-
tion for the remaining 23 patients was 5 months (range: 6 to 30). Radiological exam-
ination reviled in 6/34 (18%) patients stable disease and in the other 17/34 (50%)
progression of the disease was observed. One patient died.
There was no correlation between radioiodine avidity and clinical effect. Stagnation
of disease was observed in 3 (43%) patients with restored radioiodine uptake and
progression in 2/7 (29%). Two patients were lost from observation.
13 cis retinoic acid was well tolerated and in 85% of patients was administered in
accordance to the study protocol. Five patients had marked side effect and the
dose had to be decreased to 1 mg/kg for the whole duration of therapy. The most
frequent side effects included: dryness of lips and skin.
Conclusions: 13 cis retinoic acid can induce radioiodine uptake in about 20% of
patents with non-functioning thyroid cancer metastases. However, this effect does
not influence clinical course of the disease.
NEUROANATOMICAL  CORRELATES OF POST-STROKE
APHASIAS ASSESED BY rCBF SPECT
K. Jodzio1, D. Gąsecki2, D.A. Drumm3, P. Lass4, W. Nyka2
Institute of Psychology, Uniwersity of Gdańsk1, Poland, Department of Neurology,
Medical University of  Gdańsku, Arizona State University, Scottsdale, USA,
Department of Nuclear Medicine, Medical University of Gdańsk, Poland
Aims and background: there is no common consent, how the particular speech
functions are correlated by particular brain structures. The aim of the study was to
study neuroanatomical correlates of chosen post-stroke aphasias.
Material and methods: the study involved 50 patients with left-hemisphere stroke
and mild to moderate aphasia. To asseses the degree of aphasia Boston Diagnos-
tic Aphasia Examination (BDAE) was applied, rCBF SPECT scanning was performed
using 99mTc-HMPAO (Amersham, UK) and a triple-head gammacamera MS-3 (Sie-
mens, Erlangen, Germany). Analysed were intercerebral blood flow asymmetries
and regional cerebral blood flow normalised to cerebellar perfusion.
Results: in Broca’s aphasia dominated changes in frontal and —to lesser extent —
parietal lobe and striatum, wherease in Wernicke’s aphasia changes were seen
mostly in temporal and parietal cortex. In global aphasia SPECT scanning showed
an extensive perfusion deficit in perisylvian area and thalamus.
Conclusions: 1. Those results indicate the need of reconsideration of neuroana-
tomical correlates in aphasia, particularly the role of subcortical lesions; 2. In partic-
ular types of aphasia the patterns of rCBF changes differ; 3. rCBF SPECT scanning
should play a major role in aphasiological studies.
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rCBF SPECT SCANNING IN PATIENTS WITH PARKINSON’S
DISEASE AND DEMENTIA
M. Derejko1, P. Lass1, J. Sławek2, M. Dubaniewicz3
Department of Nuclear Medicine, Department of Neurosurgery2,
Department of Radiology3, Medical University of Gdańsk, Poland
Background and aim of the study: Dementia in Parkinson’s disease (PD) is 2–6-
fold more frequent than in the rest of population. It presents numerous diagnostic
difficulties due to lack of uniform diagnostic criteria, specificity of PD itself, including
bradyphenia and motor slowing-down and concomitant depression, which may
mimic dementia. Psychological testing may be difficult. The aim of the study was
the evaluation of the usefulness of rCBF SPECT scanning in this group of patients.
Material and methods: 44 PD patients were enrolled in the study: PD non-dement-
ed (11 patients), PD with mild, selective cognitive impairment (20 patients), PD overt-
demented patients (13 subjects); control group were 20 healthy volunteers. rCBF
SPECT has been performed using 99mTc-HMPAO (Amersham, UK) and a triple-
head gammacamera MS-3 (Siemens, Germany). Interhemispheric CBF changes
were assessed using an asymmetry index; regional CBF changes by cerebellar
normalization. MRI scanning has been performed using 0.5 T device Gyroscan
(Philips, Low Countries), white matter changes assessed in ARWMC scale.
Results: when compared with controls PD patients had significantly lower CBF in
all cerebral regions except the thalami and basal ganglia. In demented PD patients
this hypoperfusion was more pronounced in temporal and occipital lobes. The num-
ber of focal perfusion deficits in demented PD patients was significantly higher for
whole cerebellum and left, but not right hemisphere. MRI findings as measure by
ARWMC white matter changes scale were non-contributory.
Results: those results may suggest mixed vascular/neurodegenerative pathomech-
anism of cognitive impairment in PD. rCBF SPECT scanning may play an important
role in differential diagnosis of cognitive impairment in Parkinson’s disease.
THE CONNECTED PALLIATIVE THERAPY OF PAINFUL OSTEOBLASTIC-
-OSTEOLYTIC BREAST CANCER BONE METASTASES USING
RADIOISOTOPE AND BISPHOSPHONATE
M. Bączyk, R. Czepczyński, J. Sowiński
Department of Endocrinology & Department of Palliative Care Poznań University
School of Medical Sciences, Poznań, Poland
The cancer bone metastases in 75% of patients with advanced breast cancer are detected;
osteolysis predominates in 70% of cases (indication for bisphosphonate treatment), but in
30% osteoblastic component is observed, that gives the possibility for use of radioisotope
therapy. The aim of this study was to evaluate the effectivness of connected therapy using Sr89
or Sm153 and bisphosphonate therapy in the group of breast cancer patients with multiple osteo-
blastic-osteolytic (mixed) bone metastases. The study included 20 patients with breast cancer
and multiple painful bone metastases detected by scintigraphy and by radiogram or CT or MRI
(the type of metastases), with tendency to hypercalcaemia. Before (2–12 months) radioiso-
tope therapy 14 out of  20 patients have been treated with local irradiation of the bone and
bisphosphonate, but without good results. Each patient received a standard dose of stron-
tium-89 (Metastron) or samarium-153 (Quadramet) combined with intravenous infusion of
pamidronate (Aredia) or zoledronate (Zometa). The bisphosphonate therapy was repeated
every month. The group of 10 patients treated at the same time with bisphosphonate only was
observed. For assessment of therapy effectivness; pain relief (VAS scale), a reduction in anal-
gesic requirements and motor activity (ECOG and Karnofsky scale) were evaluated.
Pain relief effect Sr89 + Aredia Sm153 + Zometa Bisphosphonate
(n = 12) (n = 8) therapy only (n = 10)
Good effect VAS < 2 4 4 2
Moderate effect VAS < 5 4 3 2
No effect VAS > 5 4 1 6
During follow-up, 4 and 8 weeks after the radioisotope therapy a statistically significant pain
relief effect (VAS scale) from 7 to 4 (p < 0.05) was observed. Analgesic requirements de-
creased to 30% of dose on average. The motor activity of the points evaluated according to
ECOG scale increased from 3 to 2 and from 40 to 60 in Karnofsky scale. No pathological
fractures, hypercalcaemia, but 2 serious cases of pancytopenia with clinical manifestation
were observed. The results of treatment in the group with radioisotope and bisphosphonate
were better than in the group treated with bisphosphonates or radioisotope only.
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SENTINEL NODE BIOPSY IN TREATMENT OF PATIENT WITH MELANOMA
AMELANOTICUM OF THE PENIS — THE CASE REPORT
D. Nejc1, J. Piekarski1, P. Pluta1, J. Kuśmierek2, A. Jeziorski1
1Department of Surgical Oncology, Medical University of Łódź, 2Department of
Nuclear Medicine, Medical University of Łódź, Poland
 Melanoma amelanoticum of the penis is a rare neoplasm. In majority of cases, the
neoplasm is locally advanced on presentation. Management of primary tumor as
well as of regional lymph nodes is of a crucial importance. In many cases regional
lymph nodes are not palpable. Sentinel node biopsy allow the early detection of
metastases in lymph nodes.  We present the patient who underwent partial ampu-
tation of penis due to giant penis tumour. Postoperative histopathology revealed
melanoma amelanoticum. Prior to sentinel node biopsy the patient had lymphos-
cintigraphy with 99mTc on an albumin carrier administered into the penis stump (Nano-
coll, 72 MBq in 0.5 ml, given in 4 sites). The examination revealed lymph flow into
the inguinal lymph nodes on both sides.  Two sentinel nodes in the group of region-
al inguinal nodes on the left side, and one on the right side were identified. Sentinel
nodes biopsy was done about 24 hours after lymphoscintigraphy. Fifteen minutes
prior to biopsy 1ml of dye Patentblau V was given. Intraoperatively radiation was
measured with hand-held gamma radiation detector. Two sentinel nodes were iden-
tified in the left inguinal area, and one on the right side. The nodes dyed blue and
the radiation level was almost 20-fold higher than in surrounding tissue. The course
of lymphoscintigraphy and operation was documented by photography. Histopa-
thology (H&E) and immunochemistry (HMB 45) revealed the presence of microme-
tastasis in one of the sentinel nodes in the left groin. The patient underwent left
ilioinguinal lymphadenectomy. Examination of material obtained during operation
revealed in one of the nodes the presence of metastasis 2 mm in diameter. The
postoperative course after sentinel node biopsy and lymphadenectomy was un-
eventful. The patient received adjuvant treatment (DDP + DTIC). During 5 month
postoperative observation there was no progression of the disease. Conclusions:
Sentinel node biopsy allowed for early detection of metastases and early selective
lymphadenectomy with adjuvant therapy.
THE PRE-OPERATIVE LYMPHOSCINTIGRAPHY IS A NECESSARY PART
OF SENTINEL LYMPH NODE BIOPSY IN PATIENTS WITH SKIN
MELANOMA OF THE TRUNK
D. Nejc1, J. Piekarski1, P. Pluta1, J. Kuśmierek2, A. Jeziorski1
1Department of Surgical Oncology, Medical University of Łódź, 2Department
of Nuclear Medicine, Medical University of Łódź, Poland
Background: In Poland sentinel lymph node biopsy in skin melanoma patients is
a standard procedure in third level reference centers. The method require the spe-
cial equipment. Therefore, the availability of the method is limited.
Objectives: To assess whether it is possible not to perform a pre-operative lym-
phoscyntygraphy in patients with skin melanoma of the trunk, undergoing a sentinel
node biopsy.
Material and methods: From 1.12.1999 to 31.12.2003 in the Department of Surgi-
cal Oncology, Medical University of Łódź, in 120 patients with trunk skin melanoma
sentinel node biopsy was performed. There were 50 women (42%) and 70 men
(58%) in the studied group. Age ranged from 32 to 87 years. In all of them pre-
operative lymphoscintigraphy (Nanocoll — 2 mCi, 0,5 ml) in the Department of
Nuclear Medicine, Medical University of Łódź, intra-operative blue dye mapping
and intra-operative detection of gamma radiation were performed.
Results: Pre-operative lymphoscintigraphy allowed for the detection of sentinel
node(s) in all studied patients (100%). In 77 of them (64%) the tracer flew to one
group of regional lymph nodes. In the remaining 43 patients (36%) the tracer flew to
two or three different lymph nodes groups. Sentinel node(s) were detected intra-
operatively in 118 patients (98.3%). In all these patients sentinel nodes were identi-
fied using intra-operative detection of gamma radiation. Pigmentation of sentinel
node(s) was found intra-operatively in 90 patients (75%). The difference between
intra-operative detection rate of sentinel node using gamma-probe (98.3%) and
using blue-dye technique (75%) was statistically significant (p<0.05).
Conclusions: The pre-operative lymphoscintigraphy is a necessary part of sentinel
lymph node biopsy in patients with melanoma of the trunk. It show the directions of
lymph flow from the site of primary tumor, the site of sentinel lymph node(s) in one
or more groups of regional lymph nodes. The intraoperative assessment of radia-
tion is a main measure of sentinel lymph nodes identification; the use of blue dye is
less important.
TECHNIQUE OF SENTINEL NODE BIOPSY IN BREAST CANCER PATIENTS
— THE PERIAREOLAR INJECTION OF TRACER AND BLUE DYE
D. Nejc1, J. Piekarski1, P. Pluta1, J. Kuśmierek2, A. Jeziorski1
1Department of Surgical Oncology, Medical University of Łódź, 2Department
of Nuclear Medicine, Medical University of Łódź, Poland
Background: In breast cancer patients with negative result of sentinel node biopsy,
treated in third level reference centers, axillary lymphadenectomy is not necessary.
The method requires a special equipment and experience. Techniques used for
identification of sentinel node(s) vary: many different radiotracers could be injected
in many different sites.
Objective: Presentation of technique of sentinel node biopsy in patients with breast
cancer. Description of the method: From 1.12.1999 in Department of Nuclear Med-
icine and in Department of Surgical Oncology, Medical University of Łódź, sentinel
node biopsy is a part of treatment of breast cancer patients. Sentinel node biopsies
is performed in patients with a sole breast tumor no bigger than 3 cm, without pal-
pable axillary lymph nodes and without distant metastases, who already underwent
the wide excision of primary tumor. In all patients preoperative lymphoscintigraphy
(Nanocoll) is performed. Radiotracer is injected intradermally and periareolary; also
near the postoperative scar (after the resection of primary tumor). The location of
sentinel node is marked on the skin. Intraoperative measurements of gamma radi-
ation and blue dyeing of lymph vessels is performed (Patentblau V). Lymph node
with highest radioactivity and/or most intensive violet staining was considered as
sentinel node.
Conclusion: Using presented method, we were able to successfully identify the
sentinel notes in over 98% of patients. Our result are among the best results pre-
sented in literature. Preoperative lymphoscintigraphy shows the direction of lymph
flow and the site of sentinel nodes. The assessment of radiation performed intraop-
eratively is a main measure of sentinel node identification. The use of blue dye
makes The identification of sentinel node with the use of blue dye is easier and
faster.
RADIATION RISK DURING BREAST CANCER SURGICAL TREATMENT
WITH THE USE OF INTRAOPERATIVE HAND-HELD GAMMA-PROBE
FOR IDENTIFICATION A SENTINEL-NODE
T. Jastrzębski1, T. Bandurski2, P. Lass2
Department of Oncological Surgery1, Department of Nuclear Medicine2,
Medical University of Gdańsk, Poland
Introduction: Intraoperative hand-held gamma-probe identification of a sentinel-
node is applied more and more often. An important problem is a question of radia-
tion risk of operating staff and a problem of — happening sometimes — radiopho-
bia. The aim of the study was the radiation risk of surgeons, nurses and ancillary
personnel during such operation.
Material and methods: We studied the absorbed radiation doses of 28 persons
involved in intraoperative hand-held gamma-probe identification of a sentinel-node
in breast cancer patients: a physician who administered the radiotracer, surgeons,
assisting nurses, pathologists. Sentinel node identification was done following in-
tradermal application of 99m-Tc-nanocolloid (Amersham, England) of 0.5–1 mCi
activity. For the assessment of absorbed doses ring thermoluminescence dose-
meters (IBJ, Cracow, Poland) worn on right-hand fingers were applied. Dose-meters’
sensitivity threshold was 0.02 mSv.
Results: in 27/28 staff persons no exceeding of sensitivity threshold was showed;
in 1 nurse hand-absorbed-dose was 0.05 mSv.
Intraoperative hand-held gamma-probe identification of a sentinel-node is safe for
the personnel performing and assisting the operation.
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SENTINEL NODE IDENTIFICATION IN BREAST CANCER PATIENTS
T. Jastrzębski1, T. Bandurski2, P. Lass2
Department of Oncological Surgery1, Department of Nuclear Medicine2,
Medical University of Gdańsk, Poland
Introduction: regional lymph nodes removal is a standard element of surgical breast
cancer management. An important issue is then the identification of sentinel node
(SN), i.e. the first node in the lymph drainage from tumour’s area. The aim of the
study was to compare radionuclide and blue-dye techniques of sentinel node iden-
tification and to assess the influence of technical modalities on the result of the
study.
Material and methods: 195 patients with breast cancer were enrolled in the study
divided into three groups: group I (51 pts), where combined — blue dye/radionu-
clide SN identification has been performed; radionuclide administered around the
tumour; group II (72 pts.), where only blue dye technique was employed, group III
(72 pts.), where blue dye and radiocolloid was administered periareolarly. We used
99mTc-nanocolloid (Amersham, UK), pre-operative scintigraphy using a single-head
gammacamera Diacam (Siemens), intra-operative SN identification using hand-held
probe NeoProbe.
Results: sensitivity, specificity, positive and negative predictive value were respec-
tively: in group I: 92%, 100%, 100%, 96%; in group II 72%, 100%, 100%, 81%, in
group III 91%, 100%, 100%, 95%. An efficiency of sentinel node identification de-
pended on experience of surgeon, did not depend on age, the size of the tumour,
percentage of fatty tissue in the breast, histopathology of the tumour.
Conclusions: combined radionuclide/blue dye technique shows higher sensitivity,
specificity, positive and negative predictive in comparison to blue dye technique
applied alone.
RESULTS OF 131-I MIBG THERAPY IN MEDULLARY THYROID CANCER
S. Szpak, Z. Wygoda, D. Handkiewicz-Junak, J. Krajewska, J. Roskosz
Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie
Memorial Institute, Gliwice Branch, Poland
Meta-iodobenzylguanidine labelled with 131-I, as a catecholamine analogue, is uptaken by tumors
originating from the neural crest, therefore it is used in therapy of medullary thyroid cancer (MTC).
Material and methods: a retrospective review of 62 cycles of 131-I MIBG therapy in 35 patients was
performed. 1 cycle of treatment was performed in 21 patients. In 14 patients 2–5 cycles were per-
formed. Patients received 92–200 mCi 131-I MIBG per cycle at 3–6 monthly intervals. The cumulative
dose was 92–700 mCi (median 155 mCi). The median follow up was 24 months (0–62) from the first
131-I MIBG therapy and 62 months (3–336) from the diagnosis of MTC.
The indications to therapy were local disease (6 pts, 20%) or metastases (16 pts, 46%).
13 patients (34%) were treated due to high levels of plasma calcitonin (Ct) without known focus-
es of disease.
Results are shown in tables 1–3:
Table 1. Post-therapy scans 131I MIBG uptake:
Patients with macroscopic Uptake in all known focuses 10 48%
cancer disease Uptake in a few focuses 3 14%
 n = 21 Negative WBS 8 38%
Patients with high level Localization of disease focus 2 14%
of serum Ct without known
cancer focuses
n = 14 Negative WBS 12 86%
Table 2. 131-I MIBG therapy seldom gives objective regression.
Regression 1 3%
Stable disease 12 37%
Progression or death 17 48%
Not applicable 5 12%
Table 3. 131-I MIBG gives good palliation
Symptoms                           Response to treatment
No of Complete relief Partial relief Total no response
patients  of symptoms of symptoms
Diarrhea 8 1 3 4 (50%) 4
Pain / immobilization 3 2 1 3 (100%) 0
Dyspnoe 4 2 1 3 (75%) 1
Conclusion: 131-I MIBG treatment results in good palliative effect in 50% of patients.
The therapy should be performed only in patients with macroscopic cancer disease with a diag-
nostic evidence of sufficient tumor uptake.
LYMPHOSCINTIGRAPHY IN CERVICAL CANCER PATIENTS
D. Wydra1, S. Sawicki1, J. Emerich1, P. Lass2
Department of Gynaecology1, Department of Nuclear Medicine,
Medical University of Gdańsk, Poland
Background: Regional lymph node surgical management is an integral part of cer-
vical cancer therapy. In gynaecological oncology, recent studies have confirmed
the utility of the sentinel node concept in vulvar and cervical cancer. The method of
marker’s administration is considered to play an important role in sentinel node
detection.
Material and methods: 60 patients with cervical cancer (stage IB-IIA) underwent
SLN detection during radical abdominal hysterectomy. The patients were randomly
divided into two groups:, the first of 30 patients with 0.5–1cm deep marker injection,
the second with sub-epithelial marker injection. Gamma-camera scanning, as well
as hand-held probe detection was applied.
Results: All hot nodes visualised on lymphoscintigraphy were “hot” when using the
hand-held gamma probe. Deep marker injection revealed the sentinel node in
27 patients (90%) on both sides, in 3 patients (10%) only on one side. Only 40 (67%)
sentinel nodes were blue-stained. Sub-epithelial marker administration revealed the
sentinel node on both sides in all 30 patients (100%).  In 28 patients (93,3%) the
sentinel nodes were radioactive and blue-stained, in one case not-blue stained on
both sides, in one case blue stained only on one side.
Conclusions: The sentinel node detection rate in cervical cancer is relatively high
and depends on the applied technique. The superficial administration of radiocol-
loid and the blue dye into the cervix provides a higher sentinel node detection rate
than deep administration in cervical cancer patients.
USE OF THE 131I-LABELED MONOCLONAL ANTI-b3 ANTIBODY FOR VISUAL-
IZATION OF TUMOR NEOANGIOGENESIS
M. Bilski1, E. Lisiak1, R. Mikołajczak3, U. Karczmarczyk3, J. Pietrzykowski2,
E. Nowosielska1, M.K. Janiak1
1Military Institute of Hygiene and Epidemiology, Warsaw, Poland, 2Central Hospital,
The Ministry of Defence, Military Institute of Health Service, Warsaw, Poland,
3Research and Development Department, Radioisotope Centre Polatom, Swierk,
Otwock, Poland
Introduction: Anti-angiogenic treatment is recently drawing more and more atten-
tion. Consequently, diagnostic methods for estimation of the efficacy of such
a therapy need to be developed. Among potential candidates which could serve as
a specific benchmark is a monoclonal antibody (MoAb) directed against the b3 sub-
unit of integrin aVb3 (CD61; BD Bioscience). Conjugating this MoAb with the gam-
ma-ray-emitting short-lived isotopes might allow for imaging of radiopharmaceuti-
cal deposition using the gamma-camera-type detectors.
Material and methods: For estimation of the applicability of the anti-CD61 MoAb to
visualize tumor blood vessels in vivo, the antibody was conjugated with iodine 131I
by the standard chloramine T method (radiochemical purity of the MoAb-131I conju-
gate at 1 hour after the iodination exceeded 99%). Distribution of the conjugates in
the transplanted syngeneic tumors (as murine models of angiogenesis) was car-
ried out utilizing visualization techniques used in nuclear medicine. Biodistribution
of the conjugate in the murine body was evaluated using the same model of angio-
genesis as in the imaging studies. Results are expressed as percent of the injected
dose per gram of tissue (%ID/g), each value representing mean and SD obtained
from three animals.
Results: The intravenously applied MoAb anti-b3-
131I conjugate accumulates in the
subcutaneously growing Lewi’s lung carcinoma and remains there for 144 hours at
a high (3/1) tumor/muscle ratio. Additionally, the biodistribution reveals predomi-
nantly hepatobiliary excretion resulting in low activity in the muscles (1.16 %ID/g).
These data were confirmed by the results of the scintigraphic studies showing
a good visualization of neoangiogenesis in the tumor-bearing mice.
Conclusion: Using MoAb anti-CD61 as a radiotracer could form a basis for elabo-
ration of a non-invasive diagnostic method allowing for visualization of tumor neovas-
culature in vivo, a method useful for monitoring tumor growth and evaluation of the
efficacy of the anti-angiogenic therapy in early and later stages of the disease.
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RECOMBINANT hTSH RADIOLABELLED WITH TECHNETIUM-99m,
A NEW PROMISING RADIOPHARMACEUTICAL FOR THE DIAGNOSIS
OF METASTASES IN DIFFERENTIATED THYROID CANCER
— PRELIMINARY STUDIES
E. Byszewska-Szpocińska, U. Karczmarczyk, R. Mikołajczak
Radioisotope Centre POLATOM, Otwock-Świerk, Poland
Aim of the study: The follow-up of differentiated thyroid cancer (DTC) (after abla-
tion by iodine 131 therapy) is currently performed by whole body scan (WBS ) with
iodine 131. This technique of imaging is very often characterized by poor sensitivity
because of loss of iodine uptake capacity as the result of loss of sodium iodide
symporter receptor gene expresion (NIS) in 30% of DTC. In such cases alternative
method — imaging of TSH receptors (which are active) using radiolabelled TSH
(rhTSH) might be useful. The aim of our preliminary studies was to prepare tracer
— rhTSH labelled with technetium-99m with high specific activity, good radiochem-
ical purity and stability in vitro.
Material and methods: Recombinant human thyrotropin (rhTSH) was labelled with
technetium-99m using direct method with the addition of SnCl2 and indirect — using
the bifunctional chelating agent HYNIC (6-hydrazinonicotinamide). HYNIC-rhTSH
complex was purified on Sephadex-G-25 ( PD-10 column) and then was labelled
with technetium-99m in presence of: tricine, EDDA,EDTA as co-ligands or without
any additives alternatively. Radiochemical purity of the obtained tracers and their in
vitro stability in buffer and in human serum (370C) was studied using chromatogra-
phy on BIO-SEP-SEC-S-2000 column (gel filtration) in HPLC system and paper chro-
matography in 0.9% NaCl. Preliminary pharmacokinetic studies were performed
in healthy Swiss mice.
Results: Obtained tracers: 99mTc-rhTSH, 99mTc-HYNIC-rhTSH and 99mTc-tricine-rhTSH
revealed almost 100% radiochemical purity (Tc(VII) in pertechnetate was not detected)
and specific activity of 125 mCi/mg. 99mTc-rhTSH was very stable in vitro (in buffer and
in serum ) up to 4 hours ( radiochemical purity > 99%).Tracers: 99mTc-HYNIC-EDDA-
-rhTSH and 99mTc-HYNIC-EDTA-rhTSH showed radiochemical purity of 60 to 80% only.
The thyroid uptake of 99mTc-rhTSH tested in mice was stable and at the even level over
the period of 3 hours while in the same time fast removal from the blood was observed
(after 90 min — 50% and after 3 hours — 30% of injected dose ).
Conclusions: After labelling with technetium-99m the obtained rhTSH complexes
presented high radiochemical purity and good in vitro stability in serum. The reten-
tion of radioactivity in thyroid gives the evidence that affinity to specific receptors is
not affected by the radiolabelling process. That makes the technetium-99m labelled
rhTSH the promising candidate for further studies. Experiments in the tumor-bear-
ing animals are planned in order to verify the receptor affinity of this new tracer and
is potential as the radiopharmaceutical for diagnosis and follow up of DTC.
RHENIUM-188 SOLUTION OBTAINED FROM
THE STATIONARY 188W/188RE GENERATOR
U. Karczmarczyk, K. Chrustowski, Z. Zelek, K. Sawlewicz
Radioisotope Centre POLATOM, Świerk–Otwock, Poland
Aim of the study: Rhenium-188 is a generator produced radioisotope emitting both beta
(Eßmax = 2.1 MeV) and gamma (E? = 155 keV, 15%) radiation with the short physical half-life
of 16.98 h. Beta particles, which range of penetration in soft tissue is 3.3 mm (maximum
10.8 mm), provide radiation suitable for destroying tumour cells with little or no damage to
adjacent organs. The gamma photon can be used to monitor biodistribution and estimate
dosimetry with standard scintigraphic equipment. During last decade the interest in using
188Re for radiotherapy as well as for brachytherapy in the treatment of coronary vessels was
growing rapidly.  Because of the great interest of nuclear medicine in 188Re applications, the
technology of its manufacturing in the form of isotonic and sterile solution of sodium perrhe-
nate-188Re- has been developed at the Radioisotope Centre POLATOM.
Materials and methods: 188Re is the product of tungsten-188 decay, the latter being pro-
duced in the nuclear reactor by irradiation of tungsten enriched in 186W. The mother radio-
nuclide 188W was adsorbed on the alumina column which was conditioned with 0.9% NaCl
in 0.001 N HCl and 32% HCl. The daughter radionuclide 188Re was eluted from the column
using 0.3 M acetic acid. The obtained solution was purified and concentrated in the chro-
matographic system consisting of cation exchanger AG-50W-X12, on which the sodium
ions were adsorbed and anionic column Sep-Pak Accel Plus QMA Light, on which the
perrhenate ions were concentrated. Sodium perrhenate-188Re was eluted in small volume
(1–3 ml) of saline. The radiochemical purity of 188Re was checked by paper chromatography
in 0.9% saline. The above described stationary generator system for preparation of sodium
perrhenate-188Re has been installed in the destined hot-cells, forming a complete production
line in compliance to GMP requirements and according to ISO 9001:2002 standard.
Results: The developed method enabled preparation of the carrier-free solution of sodium
perrhenate-188Re with activity up to 180 GBq in 1 to 3 ml volume. Radiochemical purity of 188Re
solution was > 99.9% (content of 188W < 0.02%). 188W/188Re generator could be exploited over
the period of at least 6 months. The highest activity of 188Re in the eluate was obtained 3 days
after the previous elution, when the equilibrium between 188W and 188Re was reached. It was
shown that 188Re could be efficiently used for labelling of HEDP (hydroxyethylidene diphos-
phonate), radiopharmaceutical applied for palliative therapy of bone metastases.
Conclusion: The developed method for preparation of 188Re in the form of perrhenate (in
0.9% NaCl solution) using the stationary 188W/188Re generator approach (easy to operate
and safe from the radiation protection point of view) allows obtaining portions of 188Re solu-
tion with required activity and radioactive concentration, which can be further on transport-
ed to the clinics and used for patient treatment.
QUALITY CONTROL OF ITRIUM 90YCL3 MANUFACTURED AT OBRI POLATOM
A. Markiewicz, I. Sasinowska, A. Muklanowicz, W. Piecyk
Radioisotope Centre POLATOM, Otwock-Świerk, Poland
Aim of the study: Itrium-90 is widely used in nuclear medicine mostly in the form of colloids
and microspheres for radiation synovectomy. In recent years the carrier-free itrium-90 was
employed to radiolabelling of somatostatin analogues, which are used for receptor mediat-
ed radionuclide therapy of tumours, mainly of neuroendocrine origin. The advantages of
itrium as therapeutic radionuclide are its short half life (64 h), optimal beta particles energy
(2,2 MeV), decay to stable zirconium and ability to form stable complexes with various
ligands. The carrier-free Y-90 is obtained from the decay of strontium-90 and is separated
from the Sr-90 + Y-90 mixture by extraction chromatography method developed at RC
POLATOM. Itrium-90 manufactured as a precursor for labeling should conform to the qual-
itative and quantitative specification which assure its pharmaceutical usefulness. The pa-
rameters having significant influence on the quality Y-90 is radionuclidic purity (and content
of Sr-90, which is an undesired contamination due to its very long half life) and the content
of chemical impurities, such as metallic cations, which may decrease the labeling yield of
biological substances.
Materials and methods: Carrier-free itr-90 is available at Radioisotope Centre OBRI POLA-
TOM since 2003 offered as solution of Y-90 chloride with radioactive concentration >18.5
GBq/ml. Its quality is verified by checking the following parameters: 1. identification of Y-90
beta spectrum using liquid scintillation method (LSC) ; 2. content of Sr-90 determined by
chromatographic separation on the resin coated with di-t-butylcyclohexane-18-6-crown ether
(Sr-Resin) followed by LSC measurement; 3. content of traces of chemical impurities deter-
mined by the optical emission spectrometry with inductively coupled plasma (ICP-OES);
4. radioactive concentration of Y-90 in a standardized ionization chamber.
Results: Ten production batches were evaluated. In 9 of them content of Sr-90 was well
below 2.5 E-04%, in one batch the initial value of Sr-90 was higher but after additional
purification decreased to the level observed in other batches. Content of Sr-90 was deter-
mined on the production day and, in order to verify the accuracy of the method, after cool-
ing down Y-90 i.e. after about 3 months. Both measured values were in agreement in the
range of 10–15%.  ICP-OES method was used for determination of the following elements:
As, Cu, Fe, Ni, Pb, Zn. In all tested batches content of  As, Cu i Ni was below 1.0 µg/ml, Pb
— below 5.0 µg/ml, while Fe i Zn — below 10 µg/ml. Identification of Y-90 beta spectrum
was done by comparison with the Y-90 standard solution using LSC method and colegram
software. The radioactive concentration of Y-90 chloride solution determined by ionisation
chamber measurement was about 20 GBq/ml on the production day. Carrier-free Y-90 was
also used for labelling of peptides, somatostatin analogues, DOTA-TOC and DOTATATE,
and high labeling yields were obtained.
Conclusions: The methods used for quality control of Y-90 enable the determination  of
parameters critical for assessment of Y-90 chloride solution. The Y-90 manufactured at RC
POLATOM is a carrier-free preparation conforming to the following specification: content of
Sr-90 below 2.5 E-04%, content of Cu, Ni, As < 1,0 µg/ml , Pb < 5,0 µg/ml, Fe, Zn < 10 µg/ml.
The high quality of 90YCl3 is verified by the results of labelling of peptides used in receptor
mediated radiotherapy.
PRECLINICAL IN-VITRO INVESTIGATION OF DOTATATE LABELLED WITH
177Lu OR 90Y, POTENTIAL RADIOPHARMACEUTICAL FOR RECEPTOR
MEDIATED RADIOTHERAPY
D. Pawlak1, A. Korsak1, R. Mikołajczak1, E. Von Guggenberg2
1Radioisotope Centre POLATOM, Otwock, Poland, 2University Clinic for Nuclear
Medicine, Innsbruck, Austria
Aim of the study: During the last decade, due to the significant progress in various related scientific
fields (target, radio-peptide chemistry, monoclonal antibodies, biotechnology, etc.), a number of new
radionuclides, tumor antigen binding, regulatory peptide analogues and bifunctional complexing agents
are available. These are exploited for development of more effective radiopharmaceuticals suitable for
receptor mediated therapy involving the beta- and beta-/gamma-emitters. The therapeutic efficacy of
the new radiopharmaceutical depends on the ability of the carrier molecule to recognize the tumor
cells receptors and on the physical properties of the selected radionuclide (emitted radiation, energy/
range in the tissue, half-life). However, it should be remembered that the radionuclide attached to the
biological molecule may affect its receptor affinity.  The goal of this work was to establish the laborato-
ry conditions at the Radioisotope Centre POLATOM to the standard of biological in-vitro laboratory
and to perform the comparative evaluation of the therapeutic potential of a somatostatin analogue,
DOTATATE (DOTA-Phe1,Tyr3-octreotate) when labelled with 177Lu or with 90Y. The criteria used in this
evaluation were: stability of the obtained complexes after labelling, their stability in human serum and
affinity to somatostatin receptors present at the rat pancreatic tumour cells AR42J.
Material and methods: DOTATATE was received from PiChem, Austria, and the radionuclides  90Y
(carrier-free) and 177Lu (about 8 Ci/mg Lu) were obtained as chloride solutions at the Radioisotope
Centre POLATOM. The labeling was carried out in acetic buffer with addition of ascorbic acid at pH
= 4.5–5.3 followed by 30 min incubation at 90oC. The radiochemical purity of radiolabelled peptides
was determined by TLC, HPLC and SepPack separation. Human serum stability was tested at 37oC
over the period of 24 hours after labelling. The protein binding was determined using Minispin G-50
columns. The biological investigations including internalisation and  receptor affinity were carried out
on live AR42J cells at temperature 37oC during 120 minutes. For the determination of non-specific
binding the somatostatin receptors on the cells were blocked by Sandostatin or cold peptide.
Results: The complexes of DOTATATE with 90Y and 177Lu were obtained with high radiochemical
purity, over 98%. Good agreement of the results obtained using  HPLC, TLC and SepPack separation
was observed, (i.e. 24 hours after the labeling the radiochemical purity of  177Lu-DOTATATE was
respectively: 99.52%, 98.76% and 98.95%). The complexes of DOTATATE with both lanthanides are
stable at the room temperature over at least 48 hours. No significant differences between the stability
of peptide labeled with 90Y or 177Lu were observed (the radiochemical purity values were: after 4 hours
99.91% and 99.40%, after 24 hours 99.08% and 99.62% respectively). Similarly, both complexes are
stable in human serum for at least 4 hours. The protein binding is low and for both preparations is not
exceeding 2%. The investigations of cell internalization indicate that the tracers are rapidly internalizing
to the AR42J cells (about 80% for 90Y-DOTATATE and 177Lu-DOTATATE during 60–90 minutes, while
the binding to the receptors on cell surface is about 20 %). The non-specific binding is low and equal
to about  1%. The somatostatin receptor affinity of 177Lu-DOTA defined as concentration of cold pep-
tide, at which half of the receptors is saturated with the radiolabelled peptide, IC, is equal to about 40
nM, which is indicating high receptor affinity of  177Lu-DOTATATE.
Conclusions: The results of evaluation of radiolabelled peptides from the point of view of their
radiochemical purity, stability after labelling and stability in human serum as well as investigations of
somatostatin receptors affinity in AR42J cells confirm the potential usefulness of DOTATATE radio-
labelled with  both 90Y or 177Lu in receptor mediated radiotherapy.
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UTILITY EVALUATION OF 99MTC-IGG COMPLEX IN LYMPHOSCINTIGRAPHY
OF LOWER LIMBS
A. Stepien1, J. Pawlus1, M. Dziekiewicz2, J. Sroga3
1Department of Nuclear Medicine, 5th Clinical Military Hospital, Cracow;
2Department of General, Oncological and Vascular Surgery, Military Institute
of Medicine of Ministry of Defense, Warsaw; 3Clinic of General Surgery,
5th Clinical Military Hospital, Cracow;
Introduction: Lymphoscintigraphy is a very important examination in lymphoede-
ma diagnosis. This method allows  evaluate of  lymphatic system function on the
base of outflow efficiency of the tracer from site of injection, degree of its uptake in
regional lymph nodes and presence of dermal backflow.  In this method found
application some radiotracer. In last years were appeared the premises that one of
these tracers can be labeled 99m-technetium (99mTc) human polyclonal immuno-
globulin G (IgG).
Aim of the study: The purpose of this study was utility evaluation 99mTc-IgG com-
plex in lymphoscintigraphy of lower limbs.
Material and methods: Eighteen patients (mean age 54 years) suspected of lym-
phoedema of lower limbs were examined. Each patient received, in the second web
space both lower limbs, 50 MBq 99mTc-IgG complex (FAM, Lodz) in a volume 0.1–
–0.3 ml. Dynamic data acquisition with the use of X-Ring gamma camera (Mediso)
was started immediately after injection the radiotracer. The static acquisition of whole
body after 2–4 hours post injection of the tracer was performed.
Results: In all patients the radiotracer outflow from the site of injection (differentiate
in rate flow) were noticed. It allows obtained functional image of lymphatic system
lower limbs. In static phase clearly accumulation of the radiotracer in lymph nodes
of pelvis was observed. In 11 cases dermal backflow were observed on the scinti-
grams. In 7 patients clearly asymmetry in retention of the tracer in lymphatic system
were visualized. In two cases unilateral popliteal nodes were visualized. In static
phase all scintigrams clearly tissue background were shown with characteristic bio-
distribution in the plane of chest and abdominal cavity like observed post intrave-
nous injection 99mTc-IgG complex.
Conclusion: Subcutaneous injection of 99mTc-IgG complex allows dynamic and static
imaging functional lymphatic system of lower limbs. Scintigraphic traits of lymphat-
ic insufficiency after subcutaneous administration of 99mTc-IgG complex are similar
to results obtained with common using the radiotracers in lymphoscintigraphy.
OBJECTIVE EVALUATION OF VALUE RENAL OUTFLOW
(OUTPUT EFFICIENCY) FOR 99MTC-EC COMPLEX
A. Stępien1, J. Pawlus1, M. Wasilewska-Radwanska2, O. Kraft 3, V. Ullmann3
15th Clinical Military Hospital, Department of Nuclear Medicine Cracow, Poland,
2AGH University Science and Technology, Faculty of Physics and Nuclear Techniques,
Cracow, Poland, 3University Hospital, Department of Nuclear Medicine, Ostrava,
Czech Republic
Introduction: For objective evaluation of disorders renal function were applied a lot
of quantitative parameters. Save for common using, deconvolution analysis of renal
transit times of the radiotracer and analysis times of decrease in activity (T1/2), more
and more interest causes indicator outflow the tracer from kidney (Output Efficiency
— OE).
Aim: The purpose of this study was determination of cutoff level norm for renal
outflow indicator for 99mTc-EC during 30 minutes.
Material and metods: Analysis included 54 patients (mean age 49 years) with
different disorders of excretory function of kidneys. Each patient received intrave-
nous, as a bolus, technetium- 99m labeled ethylenedicysteine (99mTc-EC) (FAM Lodz)
with activity 80–100 MBq. Dynamic acquisition with using Nucline AP gamma cam-
era (matrix 64 × 64) was started immediately post administration of the tracer. The
total time of the examination was 30 minutes (60 exposures of 1 second each then
87 exposures of 20 seconds each).The kidneys were classified into three groups
using results of deconvolution analysis: group I with normal excretion (maximal transit
time (MTT) < 300 s), group II with dilatation of renal calyx-pelvis system (MTT =
= 300–600 s) and group III with blocked empting  (MTT > 600 s). Evaluation was
carried out on the excretion coefficient obtained with use of Ostnucline software
(Czech Republic).
Results:
Output Efficiency  (OE) Group I Group II Group III
Mean OE (%) 76.23 60.74 24.5
S.D. (%) 5.14 10.13 13.11
Min value OE (%) 71 28 1
Max value OE (%) 93 78 40
Number of kidneys 50 37 21
Conclusions: We shown that cutoff value of norm for indicator renal outflow 99mTc-EC
complex should exceed 71 %. This parameter can be using for objective assess-
ment of extent of disorders outflow of the radiotracer from kidneys.
CORTICAL SCINTIGRAPHY IN THE EVALUATION OF RENAL DEFECTS
IN CHILDREN WITH VESICO-URETERAL REFLUX — OPTIMIZATION
OF THE PROCEDURE AND STUDY INTERPRETATION
M. Gadzicki1, E. Młodkowska2, M. Knapska3, M. Bieńkiewicz2,
M. Kowalewska-Pietrzak4, J. Kuśmierek2
1Department of Radiology — Diagnostic Imaging, Medical University of Łódź (MUL)
2Department of Nuclear Medicine, MUL, 3Department of Endocrinology and
Radionuclide Therapy, MUL, 4Department of Pediatric Diseases, MUL, Poland
Aim of the study: The objective of this study was to evaluate the variability of the interpretation of renal
cortex scintigraphy as to the presence and severity of renal scarring.
Material and methods: Cortical renal scintigraphy with 99mTc-unitiol (the equivalent of DMSA) was
performed in 75 children with vesicoureteral reflux. 150 scintigrams of kidneys were interpreted
independently 3 times by 3 observers from different departments. Planar (PLAN) and SPECT (SPECT)
scans were classified using the modified grading system of Goldraich (G) and another scoring
system proposed by Howard (H). Indices of agreement were defined as the percentage of agree-
ment among observers and the kappa statistic.
Results: Agreement (% and kappa statistic) for different renal scan methods for each grading sys-
tem reported for kidneys and patients (mean values of three pairs of comparisons)
— kidneys (n = 150):
normal/abnormal:
PLAN: Howard: 78% (k = 0.58) Goldraich: 80% (k = 0.60)
SPECT: 65% (k = 0.35) 77% (k = 0.53)
grade of abnormality:
PLAN:  68% (k = 0.50) 66% (k = 0.49)
SPECT:  55% (k = 0.34) 63% (k = 0.48)
— patients (n = 75):
normal/abnormal:
PLAN:  78% (k = 0.51) 85% (k = 0.57)
SPECT: 59% (k = 0.20) 74% (k = 0.31)
sum of grade:
PLAN: 52% (k = 0.42) 48% (k = 0.41)
SPECT: 34% (k = 0.19) 42% (k = 0.22)
maximal grade:
PLAN: 60% (k = 0.46) 61% (k= 0.44)
SPECT: 43% (k = 0.26) 48% (k= 0.42)
Conclusions:
1. In all analyzed parameters the higher agreement was obtained for planar than SPECT scans.
2. The Grading system of Goldraich allows to obtain a higher agreement in scar detection.
3. In assessment of severity of renal scarring higher agreement was obtained when images of both
kidneys were classified separately (as kidneys rather than as patients). Higher agreement was ob-
tained when images were evaluated with respect to the maximal grade of abnormality than sum
of  grades of both kidneys.
SPECIFIC HEPATIC CLEARANCE OF 99MTc-HEPIDA — A RANGE
OF VALUES ESSENTIAL FOR CLINICAL EVALUATION OF DEGREE
OF LIVER DAMAGE
I. Frieske1, J. Kuśmierek1, J. Białkowska-Warzecha2, J. Liniecki1,
J. Kuydowicz2, M.J. Surma1
1Departament of Nuclear Medicine, Medical University, Łódź, Poland
2Department of Infectious Diseases, Medical University, Łódź, Poland
Background aim of this study: The value of total plasma clearance of 99mTc-HEPIDA
reflects in a synthetic way the degree of damage of liver parenchyma. However, a partial
elimination of this radiopharmaceutical by kidneys is a disadvantage and may bias the
evaluation of a function of liver parenchyma.
Thus, a method has been elaborated that enables determination of the specific hepatic
clearance of 99mTc-HEPIDA (ClHp).
It has been proven previously that ClHp  characterizes the liver performance more adequate-
ly than total plasma clearance of this radiofarmaceutical.
The aim of the study was the calculation of a range of values of ClHp essential
in clinical practice, necessary for interpretation to obtained results.
Material and methods: Clearance values and conventional biochemical and histo-patho-
logical evaluation of liver parenchyma were used in 134 individuals divided into 2 groups.
The first group consisted of 48 healthy volunteers (24 males and 24 females), at the age
between 19 and 55 years (av. 37). The second group contained 86 patients (53 males and
33 females), at the age of 19 to 70 years (av.43) referred from the Department of Infectious
Diseases and Hepatology of the Medical University of Łódź, with various degrees of  liver
damage in progress of chronic liver diseases (chronic viral hepatitis — 28, alcoholic disease
— 16, liver cirrhosis — 18 and other diseases: steatosis, steatohepatitis and hepatopathy
— 24 individuals).
ClHp values were determined by means of a multi-sample method, after injection 
99mTc-HEPIDA
complex. Normative values of ClHp, necessary for interpretation of results, were obtained using
a receiver operating characteristic curves (ROC) and mean values of ClHp among patients
with severe liver damage in progress of cirrhosis.
Results and conclusions: Among healthy volunteers ClHp did not show dependence on
age. Mean values in males were somewhat higher that in females (p = 0.005), but lower bound-
aries of normal values for ClHp (mean — 2SD) were similar among both sexes (119 ml/min/
/1.73 m2 in males and 114 ml/min/1.73 m2 in females). In that case, further consideration of
normative values for both sexes together was recognized as sensible.
The following ranges of values of ClHp, important for the practical interpretation of results,
were isolated:
— above 150 ml/min/1.73 m2 — excluding with probability of about 90% the presence of
significant liver damage;
— up to 130 ml/min/1,73 m2 — pointing at liver parenchyma damage with probability of
about 90%;
— between 130 and 150 ml/min/1,73 m2 — only suggesting the impairment of liver function;
— equal or below 80 ml/min/1,73 m2 — pointing at considerable liver damage (typical for
the liver cirrhosis).
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NUCLEAR MEDICINE/ELECTRORADIOLOGY TECHNOLOGISTS:
THE CONCEPTS OF MSC STUDIES AT MEDICAL UNIVERSITY
IN GDAŃSK
P. Lass
Department of Nuclear Medicine, Medical University of Gdańsk, Poland
Transfer of training of s.c. paramedic professions to medical universities in Poland
and in Europe is slow, but progressive. In Poland BSc studies in electroradiology
were established at medical universities in Gdańsk (2001), Warsaw (2002) and
Poznań (2003). In Medical University of Gdańsk first diplomas of BSc. of medical
techniques (electroradiology) will be handed over in 2004. According to the logic of
s.c. Bologna Formula — L/M/D — Licentiate/Master/Doctorate in academic year
2003/2004 will start the supplementary Master studies. Because of no pattern to
follow (British and Dutch models are not applicable) as a goal to be achieved we
applied the professional model of future MSc., as a supervisor of technical staff,
member of administrative staff, member of research groups and a teacher.
In conclusion, two models of MSc. studies are considered:
a) full time MSc. studies: in large scale elective, assuming developing BSc. studies
in choice of three out of five specializations: diagnostic imaging, radiotherapy (oblig-
atory on of those two), paedagogics and methodology of research, economics and
administration, radiological informatics with curriculum of ca. 800–1000 h/year.
b) evening classes with curriculum 300–350 h/year, 20% of elective hours; 40% of
diagnostic imaging and radiotherapy, 40% of general subjects (philosophy, lan-
guages, paedagogics and methodology of research)
Conclusive remarks: fulfilling the expectations outlined above depends on a) state
of law in Poland (the project of Act on Medical Professions is still not accepted by
the Parliament); b) education concepts of the Ministry of Health and Ministry of
Education, c) financial moves resulting from the pt. a) and b); d) local educational
concepts and possibilities of particular universities, as well as supervising concepts
of State Accreditation Commission.
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ACCURACY AND PRECISION OF 99MTC-HEPIDA CLEARANCE
DETERMINATIONS
M.J. Surma
Department of Nuclear Medicine, Institute of Radiology — Medical Imaging
and Nuclear Medicine, Medical University of Łódź, Poland
In the Department of Nuclear Medicine of the Medical University of Łódź an advanced method has
been introduced for determination of the specific hepatic plasma clearance of 99mTc-HEPIDA. The
hepatic clearance (ClHp) is being determined as a difference between plasma clearance (ClPl) and
urinary clearance (ClUr) of the substance.
The objective of this study was to obtain information regarding accuracy and presision of ClPl and
ClHp of 
99mTc-HEPIDA.
Material and methods: As there is no objective standard of 99mTc-HEPIDA clearance, the assess-
ment of accuracy and precission has been based on simulation utilizing the randomised Monte
Carlo procedure. In the experiment it was assumed, that results of plasma 99mTc-HEPIDA concentra-
tion decay curves, obtained in 185 patients and volunteers, reflect properly true clearance of plas-
ma in a wide range of rates of the process. The decline has been described by fitting a biphasic
exponential function whose four parameters may be obtained by iterative least square fitting of time
points concentrations CPl(t) to the presumed model. It had been assumed also that urine retention in
the bladder (after voiding) may be neglected. For each clearance curve, as obtained from 185
studied individuals, 5000 samplings were made, in which the time decay of plasma concentrations
was randomly varied by means of incidental factors of normal distribution. These factors corre-
sponded to errors of plasma and standard solution (activity standard) pipetting (from 1 to 5%) and
to stochastic variation of the count-rate (1%). The so obtained values of plasma concentration (99mTc-
HEPIDA) were then used to compute the calculated clearances, and by utilizing the principles of
error propagation for assessing the estimator of the error of determined value of the clearance,
called here uncertainity of the result. From 5000 random trials the means, their mean square errors
and mean ancertainties were computed.
The accuracy of clearance determination was then evaluated by comparing mean of the calculated
clearance with those originally determined. Comparison of mean uncertainities with the mean square
error permitted evaluation of the degree of agreement of the estimator with the error. As a measure
of precision a coefficient of variationwas used, i.e. quotient of the mean uncertainity and the mean
clearance value.
Results. Accuracy. There was a very tight correlation between the determined clearance and the means
from computed values (r$0.98 in all cases). The computed lines of regression are practically overlying
the lines of identity. These correlations are practically not affected by the uncertainity of pipeting.
The precision, to the contrary, depends to a substantial degree upon uncertainty of the pipetting.
For plasma clearance value (ClPl) > 300 ml/min and at pipetting uncertaininty of 2%, the coefficient
of variations amounts to 6%; at low values of 80 ml/min the c.v. will rise to 12%.
For the specific hepatic clearance (ClHp) the coefficient of variation at 300 ml/min eqals 7.5%; at
values characterisung serious pathology i.e. 50 ml/min it will reach 20%.
Conclusions. 1. Methods for determination of 99mTc-HEPIDA clearance are sufficient accurate for
purposes of clinical diagnosis.
2. The precision of ClPl depends primarily on the magnitude of the ClPl and for a wide range of
encountered values varies from 6 to 12 %.
3. Precision of ClHp is somewhat less favourable. At ClHp = 300 ml/min it amounts to 7.5%, at 150 ml/min,
wich is a lower boundary of normal values, it amounts to 12%. At low values of ClHp which characterise
serious liver parenchyma damage, e.g. 130 ml/min, coefficient of variations reaches 16%.
RENAL SCARS IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS
A. Szadkowska1, M.J. Surma2, E. Mlodkowska2, J.Kuśmierek2,
W. Andrzejewski1, J. Bodalski1
1Department of Children Diseases, Institute of Pediatrics, 2Department of Nuclear
Medicine, Institute of Radiology, Medical University of Łódź, Poland
Nephropathy is one of the main diabetic complications. Nowadays research results
show that in patients with diabetes not only glomerulopathy but also interstitial le-
sions were found. These complications can be caused by chronic inflammatory
process connected with diabetes.
Aim of the study: To estimate the frequency of the incidence of renal scars in type
1 diabetic adolescents.
Research group and methods: 30 patients (15 male, 15 female) at the age 19.2 ±
± 4.2 years were included in the study. Duration of diabetes was 12.1 ± 5.2 years.
38 healthy individuals (18 male, 20 female) at the age 19.5 ± 1.3 without any history
of kidney disease were the control group. Renal scinthigraphy using 99mTc-EC was
performed. The results of examination underwent computer analysis according to
an own program to obtain renographic curves and parametric clearance images.
On these images the regions of local disturbances or lack of clearance function was
recognized as scars. They were mainly localised in peripheral parts of kidneys.
Each examination was evaluated by two independent researchers.
Results: The renal scars were found more frequent in patients with diabetes than in
control group (12/30 patients with diabetes — 40% vs in 6/38 control group
— 15.8%, p < 0.05). In the diabetic patients the scars were noticed in both kidneys
in 7 individuals, and in one kidney in 5 patients. In the control group scars were
observed in both kidneys in 3 individuals and in one kidney in 3 persons. The scars
were mainly found in the upper pole and lower region of the kidneys.
Duration of diabetes was a little longer in the patients in whom renal scars were rec-
ognized than in the patients without renal scars (13.3 ± 5.9 vs.11.8 ± 4.6 years, NS).
Conclusion: In the diabetic patients the renal scars occurred above twice more
frequently than in the control group. This observation need future investigation based
on larger study group.
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